Efficacy and safety of a new inactivated vaccine against the rabbit haemorrhagic disease virus 2-like variant (RHDV-2)
Efficacy and safety of a new inactivated vaccine against the rabbit haemorrhagic disease virus 2-like variant (RHDV-2)
In 2010 a new variant of rabbit haemorrhagic disease (RHDV-2) emerged in France and quickly spread through several European countries, causing atypical outbreaks in commercial rabbitries. Classical RHDV vaccines showed low cross-protection against RHDV-2, revealing the need for a specific vaccine against the disease. In this study the efficacy and safety of ERAVAC, an inactivated vaccine developed by HIPRA for preventing RHDV-2, was evaluated and compared with its simultaneous administration with a classical RHDV vaccine (Cunipravac RHD).
Acerca deste artigo
Produtos relacionados
The contents of this page are country specific and aimed specifically at prescribing veterinarians.
This product is not available in {{ preferredCountry.title }}.
You will be redirected to our global site. Click on continue to visit our global site (available in English).
Confirm that you are a veterinary professional:
- I am a veterinarian (otherwise please contact a veterinary professional)
Select your country:
- Global (available in English)
- {{country.title}}
